Biggest Seed, Series A-E and Venture Investments within Oncology April 2024.
View the report at the bottom of this page.
April 2024 Snapshot:
173 Companies across EU and US were involved in some sort of cash movements (all indications, all cash types). From this $ 3,429,771,999 total true investment received in USA and EU within the Oncology sector in March 2024 across 53 different biotechs.
Some Notable True Oncology Investments
✅Diagonal Therapeutics - $128,000,000 (Series A): Pioneer a New Approach to Discovering and Developing Agonist Antibodies
✅Obsidian Therapeutics - $ 161,000,000 (Series C): Advance lead engineered tumor-infiltrating lymphocyte (TIL) program in its ongoing trials for patients with melanoma and non-small cell lung cancer
✅SalubrisBio - $ 35,000,000 (Series A): research and development of clinical and pre-clinical programs
✅Flindr Therapeutics - $ 21,376,154 (Series A): Advance first-in-class small molecule inhibitors
✅Pathios Therapeutics - $ 25,000,000 (Series B): Advance Lead Candidate into the Clinic and Expand Leadership Team to Align with its Transition into a Clinical-Stage Company
✅ Plus 40+ companies in the report.
Download the full report here.
